Patents Examined by Charanjit Aulakh
  • Patent number: 11891363
    Abstract: Multitarget-directed compounds combining the features of reactive oxygen species (ROS) modulators, poly (ADP-ribose) polymerase 1 (PARP1), and/or heat shock protein 90 (Hsp90) inhibitors in a single molecule. These single agents constitute a systemic regimen for treating the triple-negative breast cancer phenotype that overcomes drug resistance and tumor recurrence, and may be used for other indications as well, such as the treatment of various neurodegenerative disorders.
    Type: Grant
    Filed: June 30, 2023
    Date of Patent: February 6, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Saad Shaaban, Hany Mohamed Abd El-Lateef Ahmed, Bander Alshemary
  • Patent number: 11890275
    Abstract: The present embodiments relate to substituted heterocyclic derivative therapeutic compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of diseases mediated by aberrant cell signalling, such as inflammatory disorders, cancer and neoplastic disease. Particular compounds described herein exhibit selective inhibitory activity against CBP compared with BRD4.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: February 6, 2024
    Inventors: Lynnie Trzoss, Juan Manuel Betancort, Toufike Kanouni, Michael Brennan Wallace, Amogh Boloor
  • Patent number: 11884679
    Abstract: Provided is a compound including a moiety A and one or two moieties B fused with the moiety A at fusing sites, in which X is N, O, S or C; and when X is O or S, Ar2-L1- is absent; Y1-Y4 are each independently C or N; L1 and L2 are each independently a single bond, a substituted or unsubstituted C6-C30 arylene, a substituted or unsubstituted C10-C40 fused arylene, or a substituted or unsubstituted C4-C30 heteroarylene; Ar1 and Ar2 are each independently a substituted or unsubstituted C6-C30 aryl, a substituted or unsubstituted C10-C40 fused aryl, a substituted or unsubstituted C4-C30 heteroaryl, or a substituted or unsubstituted C6-C40 fused heteroaryl, and * represents one of the fusing sites, N or CRa, where Ra is a substituted or unsubstituted C1-C20 alkyl, a substituted or unsubstituted C6-C30 aryl, or a substituted or unsubstituted C3-C30 heteroaryl.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: January 30, 2024
    Assignees: WUHAN TIANMA MICRO-ELECTRONICS CO., LTD., WUHAN TIANMA MICROELECTRONICS CO., LTD. SHANGHAI BRANCH
    Inventors: Wenpeng Dai, Wei Gao, Lei Zhang, Quan Ran
  • Patent number: 11884664
    Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: January 30, 2024
    Assignee: Array BioPharma Inc.
    Inventors: James Francis Blake, Mark Laurence Boys, Mark Joseph Chicarelli, Adam Wade Cook, Mohamed S. A. Elsayed, Jay Bradford Fell, John P. Fischer, Ronald Jay Hinklin, Yutong Jiang, Oren Teague McNulty, Macedonio J. Mejia, Martha E. Rodriguez, Christina Elizabeth Wong
  • Patent number: 11884651
    Abstract: A 7-(4-((4-benzylidene-5-oxo-2-phenyl-4,5-dihydro-1H-imidazol-1-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid compound, its synthesis, and its use as an anti-inflammatory agent.
    Type: Grant
    Filed: September 20, 2023
    Date of Patent: January 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11878988
    Abstract: A series of functionalized imidazophenthridine analogue-based blue phosphorescent emitters have been designed, where bulky substituents (e.g., tetrabutyl, phenyl, mesityl, triisopropylbenzene, etc.) are introduced on an imidazophenthridine fragment of the emitters. Bulky substituents may suppress potential excimer formation, as well as improve the solubility of the complexes. This class of emitters may be utilized in luminescent labels, emitters for organic light emitting devices, and lighting applications.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: January 23, 2024
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Jian Li, Linyu Cao
  • Patent number: 11873300
    Abstract: Crystalline forms of Compound I: pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: January 16, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Yi Shi, Kevin J. Gagnon, Jicong Li, Jennifer Lu, Ales Medek, Muna Shrestha, Michael Waldo, Beili Zhang, Carl L. Zwicker, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • Patent number: 11865108
    Abstract: Nitrogen containing bicyclic compounds of Formula (I), pharmaceutical compositions comprising these compounds and their use in treating bacterial infection is disclosed.
    Type: Grant
    Filed: October 18, 2020
    Date of Patent: January 9, 2024
    Assignee: Wockhardt Limited
    Inventors: Vijaykumar Jagdishwar Patil, Ravikumar Tadiparthi, Rajib Bhuniya, Vikas Vitthalrao Deshmukh, Zaki Ahmed Burhanuddin Munshi, Piyush Ambalal Patel, Prashant Ratnakar Joshi, Rajesh Chavan, Swapna Shripad Takalkar, Ravindra Dattatraya Yeole, Mahesh Vithalbhai Patel
  • Patent number: 11858933
    Abstract: The invention provides a novel class of therapeutics that are safe and effective inhibitors of Janus kinase 1 and pharmaceutical composition and methods of preparation and use thereof in the treatment of various diseases and disorders (e.g., inflammatory diseases, immune-mediated diseases or cancer).
    Type: Grant
    Filed: June 30, 2023
    Date of Patent: January 2, 2024
    Assignee: LYNK PHARMACEUTICALS CO. LTD.
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez
  • Patent number: 11858930
    Abstract: The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: January 2, 2024
    Assignee: JAZZ PHARMACEUTICALS IRELAND LIMITED
    Inventors: Andrew Belfield, Clifford David Jones, Jean-François Margathe, Chiara Colletto
  • Patent number: 11851431
    Abstract: The invention provides a novel class of therapeutics that are safe and effective inhibitors of Janus kinase 1 and pharmaceutical composition and methods of preparation and use thereof in the treatment of various diseases and disorders (e.g., inflammatory diseases, immune-mediated diseases or cancer).
    Type: Grant
    Filed: June 30, 2023
    Date of Patent: December 26, 2023
    Assignee: LYNK PHARMACEUTICALS CO. LTD.
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez
  • Patent number: 11856840
    Abstract: Iridium, rhodium, and platinum complexes suitable for use as phosphorescent emitters or as delayed fluorescent and phosphorescent emitters having the following structures:
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: December 26, 2023
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Jian Li, Guijie Li
  • Patent number: 11845759
    Abstract: This invention relates to novel opioid derivatives of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R3, R4 and Z are as defined herein in the disclosure. The invention also relates to the use of such compounds for the treatment or prevention of, for example, pain.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: December 19, 2023
    Assignee: RHODES TECHNOLOGIES
    Inventors: Ping Chang, Raymond Glowaky, Michael David Rogers
  • Patent number: 11845747
    Abstract: The invention provides compounds of formula (I): or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases and release an active metabolite in vivo. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat inflammatory skin diseases and other diseases.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: December 19, 2023
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Philip A. Gerken, Jianhua Chao, Daniel D. Long
  • Patent number: 11845748
    Abstract: The present invention is directed to bicyclic pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: December 19, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Zhijie Liu, Micheal D. Gaul
  • Patent number: 11839216
    Abstract: The present disclosure discloses a quinoline-2,3-fused nine-membered ring scaffold compound, and a preparation method and application thereof as an effective component in a plant fungicide. The quinoline-2,3-fused nine-membered ring scaffold compound stated in the present disclosure is prepared by the following method including steps: mixing a quinoline-derived aniline compound and a formaldehyde compound, adding a solvent and a catalyst, controlling a system temperature, and reacting with stirring to obtain a quinoline-2,3-fused nine-membered ring compound. According to the present disclosure, a 1,6-hydride transfer/cyclization strategy is triggered by aldimine condensation, the quinoline-derived aniline compound and the formaldehyde compound are prepared into the quinoline-2,3-fused nine-membered ring compound with a wide substrate scope and a potential biological activity by a “one-pot synthesis method” quickly.
    Type: Grant
    Filed: February 8, 2023
    Date of Patent: December 12, 2023
    Assignee: QINGDAO AGRICULTURAL UNIVERSITY
    Inventors: Xiao-De An, Jian Xiao, Daying Shao, Bin Qiu
  • Patent number: 11833138
    Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain glycerol and an amount of apixaban in the solution phase of the formulations of from 0.5 mg/ml to 6 mg/ml.
    Type: Grant
    Filed: January 30, 2023
    Date of Patent: December 5, 2023
    Assignee: TaP Pharmaceuticals AG
    Inventors: Nilesh Parikh, William Hite
  • Patent number: 11833146
    Abstract: There is provided a therapeutic agent for Alzheimer's disease and Lewy body dementia for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (1): or a pharmaceutically acceptable salt thereof, and donepezil represented by formula (II): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: December 5, 2023
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mai Miyamoto, Sadaharu Kotani
  • Patent number: 11834458
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: December 5, 2023
    Assignee: NUVATION BIO INC.
    Inventors: David Hung, Jayakanth Kankanala, Christopher Paul Miller, Jeremy David Pettigrew, Son Minh Pham, Ihab S. Darwish
  • Patent number: 11827621
    Abstract: Disclosed are small molecule inhibitors of ?v?6 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: November 28, 2023
    Assignee: Morphic Therapeutic, Inc.
    Inventors: Mark Brewer, Matthew G. Bursavich, Aleksey I. Gerasyuto, Kristopher N. Hahn, Bryce A. Harrison, Kyle D. Konze, Fu-Yang Lin, Blaise S. Lippa, Alexey A. Lugovskoy, Bruce N. Rogers, Mats A. Svensson, Dawn M. Troast